Ying Cheng
YOU?
Author Swipe
View article: Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Multivariable Cox regression analysis of determinants of PFS
View article: Supplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) The Kaplan-Meier curve of overall survival (OS) in the per protocol set. (B) The Kaplan-Meier curve of OS adjusted by a two-stage estimation method based on the rank preserving structural failure time (RPSFT) model. The tick marks indi…
View article: Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Treatment-related adverse events in treated patients with MET amplification and/or MET IHC 2+/3+
View article: Supplementary Figure S3 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Supplementary Figure S3 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA Open
Kaplan–Meier estimates showing OS in all trial patients with a valid baseline (detectable or non-detectable) plasma ctDNA result in A, patients from the AURA3 trial (n = 291) and B, patients from the FLAURA trial (n = 499). Censored data a…
View article: Supplementary Table S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Supplementary Table S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA Open
Representativeness of study participants
View article: Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
Multivariable Cox regression analysis of determinants of OS (without consideration of crossover)
View article: Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Outcomes of treatment for all individuals enrolled
View article: Supplementary Figure S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Supplementary Figure S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA Open
Correlation between EGFRm allelic fraction at baseline by ddPCR (Biodesix) and NGS (Guardant Health) analyses in A, patients from the AURA3 trial (n = 202) and B, patients from the FLAURA trial (n = 347). Abbreviations: ddPCR, droplet digi…
View article: Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 mon…
View article: Supplementary Figure S4 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Supplementary Figure S4 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA Open
Assessment of correlation between EGFRm VAF in baseline plasma and investigator-assessed PFS in A, patients from the AURA3 trial, by treatment arm and B, patients from the FLAURA trial, by treatment arm. Abbreviations: CR, complete respons…
View article: Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial Open
The Kaplan-Meier curve of progress-free PFS in the Per-Protocol Set. The tick marks indicate censored data.
View article: Supplementary Figure S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Supplementary Figure S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA Open
AURA3 flow diagram for ctDNA analysis (n = 291). Clearance refers to non-detectable plasma EGFRm, where EGFRm was detectable at baseline. *There were 9 patients in the osimertinib arm and 1 patient in the platinum-pemetrexed arm without a …
View article: Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Open
Demographic data of all individuals enrolled
View article: Supplementary Figure S6 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Supplementary Figure S6 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA Open
Kaplan–Meier estimates showing investigator-assessed PFS in FLAURA trial patients by clearance or non-clearance of plasma EGFRm status at Weeks 3 or 6 in patients who had baseline detectable plasma EGFRm. For comparison, patients with base…
View article: A study of the predictive value of transcranial doppler ultrasound for intracranial infections and the distribution of causative organisms
A study of the predictive value of transcranial doppler ultrasound for intracranial infections and the distribution of causative organisms Open
View article: Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming
Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming Open
The KRAS mutation represents the most prevalent oncogenic alteration observed in human cancers. Its primary role involves directly driving malignant tumor development and growth through the activation of downstream signaling pathways. Incr…
View article: A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America
A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America Open
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis and accounts for approximately 11% of all lung cancers. Owing to the complex and aggressive nature of the disease, clinical management of SCLC is…
View article: LLMs4All: A Review of Large Language Models Across Academic Disciplines
LLMs4All: A Review of Large Language Models Across Academic Disciplines Open
Cutting-edge Artificial Intelligence (AI) techniques keep reshaping our view of the world. For example, Large Language Models (LLMs) based applications such as ChatGPT have shown the capability of generating human-like conversation on exte…
View article: Effect of Refining Temperature and Refining Time on Purification and Composition Control of FGH95 Powder Metallurgy Superalloy Return Material During Vacuum Induction Melting
Effect of Refining Temperature and Refining Time on Purification and Composition Control of FGH95 Powder Metallurgy Superalloy Return Material During Vacuum Induction Melting Open
To promote the high-value recycling of machining return materials from powder metallurgy (P/M) FGH95 superalloy production, a vacuum induction melting refining process was developed to achieve gas impurity purification and compositional co…
View article: IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer Open
Patients with small cell lung cancer (SCLC) have poor prognosis and limited treatment options beyond first-line therapy. B7 homolog 3 (B7-H3) is minimally expressed in normal tissues but highly expressed in SCLC. Ifinatamab deruxtecan (I-D…
View article: Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors—A phase 1/1b study
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors—A phase 1/1b study Open
QL1706 has shown promising efficacy in solid tumors in a phase 1/1b study. Here, we report updated long-term survival outcomes and biomarker analyses. Among 468 patients treated with QL1706 (5 mg/kg), median progression-free survival (mPFS…
View article: Indoor WiFi fingerprint localization based on dual population PSO of stacked autoencoder and multi label classification
Indoor WiFi fingerprint localization based on dual population PSO of stacked autoencoder and multi label classification Open
View article: Integrated machine learning analysis of 30 cell death patterns identifies a novel prognostic signature in glioma
Integrated machine learning analysis of 30 cell death patterns identifies a novel prognostic signature in glioma Open
Background Glioma heterogeneity and therapeutic resistance are closely linked to dysregulated programmed cell death (PCD). While individual PCD pathways have been studied, the integrated network of multi-modal PCD interactions and their cl…
View article: Dataset of personal protective equipment
Dataset of personal protective equipment Open
View article: Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial Open
We aimed to assess the tolerability and efficacy of finotonlimab (an anti-programmed cell death protein-1 antibody) in combination with SCT510, a bevacizumab biosimilar, versus sorafenib in unresectable advanced HCC. This randomized phase …
View article: Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 5. The exploratory analysis of PFS according to HVEM and PD-L1 expression.
View article: Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 3. Treatment-related treatment-emergent adverse events occurring in ≥5% of all patients.
View article: Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 2. Representativeness of study participants.
View article: Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 2. Kaplan-Meier estimation of DOR.
View article: Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 1. Subsequent systemic antitumor therapy.